相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
Mark Andrew Dickson et al.
INVESTIGATIONAL NEW DRUGS (2011)
Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON?
Harold J. Burstein
JOURNAL OF CLINICAL ONCOLOGY (2011)
Hsp90 Inhibitor-Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage
Kyungsoo Ha et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines
Adriano Angelucci et al.
GYNECOLOGIC ONCOLOGY (2010)
Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells
Taofeek K. Owonikoko et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
Anne Hansen Ree et al.
LANCET ONCOLOGY (2010)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Role of acetylation and extracellular location of heat shock protein 90α in tumor cell invasion
Yonghua Yang et al.
CANCER RESEARCH (2008)
A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Thehang H. Luu et al.
CLINICAL CANCER RESEARCH (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-α levels and transcriptional activity:: A result of hyperacetylation and inhibition of chaperone function of heat shock protein 90
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2007)
Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2
P Bali et al.
CLINICAL CANCER RESEARCH (2005)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase
AI Marcus et al.
CANCER RESEARCH (2005)
Heat shock protein 90 as a molecular target for cancer therapeutics
JS Isaacs et al.
CANCER CELL (2003)
HDAC6 is a microtubule-associated deacetylase
C Hubbert et al.
NATURE (2002)
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
CF Deroanne et al.
ONCOGENE (2002)
Histone deacetylase inhibitors as new cancer drugs
PA Marks et al.
CURRENT OPINION IN ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
